This study is a single-center, open Phase I study, to observe the effectiveness and safety of
CT103A combined with different doses of Selinexor in patients with relapsed/refractory
extramedullary multiple myeloma, and the pharmacokinetics of Selinexor and CT103A Kinetic and
In this study, two dose groups of 20 mg/week and 40 mg/week will be set for Selinexor, and
the dose of CT103A is 1.0×106 cells/Kg. Subjects in all dose groups will firstly receive a
single dose infusion of CT103A, at least 1 month post infusion and platelet recovery to
≥50×109/L. Then subjects began to take Selinexor once a week for one year. Each dose group
level will include 8-10 subjects, and a total of 16-20 subjects are expected to be enrolled.
If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.
Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.